GLP-1 weight loss drugs are approved and studied for children with obesity
Updated
Updated · The New York Times · May 6
GLP-1 weight loss drugs are approved and studied for children with obesity
13 articles · Updated · The New York Times · May 6
Several are FDA-approved for children aged 10 and older with obesity or Type 2 diabetes, while a University of Minnesota-led study is testing them in children as young as six.
Early findings suggest benefits similar to adults, including better blood pressure, blood sugar and cholesterol, with mainly short-term side effects such as nausea and vomiting.
Debate persists over ethics, development and long-term health effects, as paediatric studies last only up to 18 months and treatment may need to continue indefinitely.
What are the hidden long-term risks for children taking GLP-1 drugs—are we trading short-term benefits for unknown developmental costs?
With so many barriers to access, could GLP-1 drugs worsen health inequities among children struggling with obesity?
Expanding GLP-1 Obesity Treatments: Efficacy, Safety, and Access Barriers in Adolescents and Adults
Overview
Between 2022 and 2026, significant FDA approvals advanced obesity treatment, including Wegovy for adolescents 12 and older and Foundayo, an oral GLP-1 receptor agonist, for adults. Foundayo's oral form offers greater convenience, potentially boosting adherence and fueling a projected rise in GLP-1 use. While these medications effectively reduce weight, common gastrointestinal side effects can lead to discontinuation, and rare serious risks require monitoring. Mental health concerns, initially prompting regulatory reviews, were later eased after comprehensive studies found no increased suicidal risk. However, long-term safety data, especially for children under 12, remain limited, underscoring the need for ongoing surveillance. Access barriers like high costs, insurance gaps, and racial disparities continue to limit treatment reach, highlighting the importance of integrated care and policy reforms.